logo

For the Inventor, By the Inventor

Millburn, NJ, United States of America

Ying Li

This inventor holds 27 USPTO granted patents and 5 published patent applications and 10 EPO patents, primarily in Pharmaceutical Formulations. Top assignees: Celgene Corporation, Signal Pharmaceuticals, Inc., Celgene Car LLC. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ying Li. Retrieved from https://idiyas.com/inventor/ying-li-01sstmzi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 

% Patents Active = 77.8

 

Average Co-Inventor Count = 5.3

ph-index = 7

Forward Citations = 110(Granted Patents)


Location History:

  • Springfield, NJ (US) (2014 - 2017)
  • Millburn, NJ (US) (2016 - 2023)

Company Filing History:

goldMedal16 out of 561 
 
Celgene Corporation
 patents
silverMedal5 out of 169 
 
Signal Pharmaceuticals, Inc.
 patents
bronzeMedal4 out of 44 
 
Celgene Car LLC
 patents
4. 2 out of 23 
 
Neuralstem, Inc.
 patents

Years Active: 2014-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
Pharmaceutical Formulations
Solid Forms
MK2 Inhibitor
Piperidine
Compositions
Neurostimulative
Dihydropyrazino
Quinazolin
Chemical Synthesis
Compositions of Salts
Piperazine
Processes
27 patents (USPTO):Explore Patents
1. 12343346 - Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same (2025-07-01),
2. 11629153 - Forms and compositions of a MK2 inhibitor (2023-04-18),
3. 11401257 - Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses (2022-08-02),
4. 11241439 - Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same (2022-02-08),
5. 10882867 - Forms and compositions of a MK2 inhibitor (2021-01-05),
6. 10626101 - Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses (2020-04-21),
7. 10604510 - Solid forms comprising (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[B]azepine-4-carboxami compositions thereof, and uses thereof (2020-03-31),
8. 10596180 - Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl) oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same (2020-03-24),
9. 10463672 - Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same (2019-11-05),
10. 10202364 - Forms and compositions of an ERK inhibitor (2019-02-12),
11. 10189808 - Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses (2019-01-29),
12. 10005760 - Forms and compositions of an ERK inhibitor (2018-06-26),
13. 9969713 - Solid forms of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses (2018-05-15),
14. 9884062 - Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same (2018-02-06),
15. 9827243 - Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one (2017-11-28),

Title: Innovations and Contributions of Ying Li: A Leading Inventor in Pharmaceutical Development

Introduction: Ying Li, an accomplished inventor based in Millburn, NJ, has made significant contributions to the field of pharmaceuticals with a remarkable portfolio of 26 patents. His innovative research has focused on developing novel compounds and compositions, particularly in the area of MK2 inhibitors.

Latest Patents: Among his latest patents, Ying Li has introduced solid forms of an MK2 inhibitor, which encompass compositions and methods of use. This invention presents a significant advancement in pharmaceuticals by providing solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide. The patent details not only the solid forms but also the methods for their creation and various potential applications.

Career Highlights: Ying Li's career spans prominent roles at leading pharmaceutical companies, including Celgene Corporation and Signal Pharmaceuticals, Inc. His work has had a profound impact, particularly in drug development and innovation.

Collaborations: Throughout his career, Ying has collaborated with esteemed colleagues, including Jean Xu and Benjamin M Cohen. These partnerships have enabled the exchange of ideas and fostered advancements in the pharmaceutical industry.

Conclusion: With 26 patents to his name, Ying Li continues to be a pioneering figure in the world of pharmaceutical innovations. His work on MK2 inhibitors represents just a glimpse of his potential to drive future advancements in the field. As he continues his endeavors, the scientific community eagerly anticipates the next breakthroughs that may emerge from his research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…